An alternative method to validate surrogate endpoints in oncology

Surrogate endpoints are often utilized to support drug efficacy claims. Hence, it is of paramount importance to validate the effectiveness of surrogate endpoints in correctly predicting clinical benefit, in order to ensure a fast and safe access to new drugs. This study aimed to explore the applicability of Receiver Operating Characteristic (ROC) curve and its Area Under Curve (AUC) for trial-level surrogate validation, and to compare the predictive power of surrogate threshold effects (STE) der